Continuing evidence to support the role of early kinetic monitoring in predicting sustained viral response for HIV/HCV co-infected patients by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Journal of the International AIDS 
Society
Open AccessPoster presentation
Continuing evidence to support the role of early kinetic monitoring 
in predicting sustained viral response for HIV/HCV co-infected 
patients
J Kieran*, A Jackson, DO Shea, G Farrell, J Thornhill, C McNally, F Mulcahy 
and C Bergin
Address: St James Hospital, Dublin, Ireland
* Corresponding author    
Background
Hepatitis C virus (HCV) is a major cause of chronic liver
disease and requirement for liver transplantation. Shared
acquisition risk factors mean that HIV co-infection is com-
mon. Co-infection has been shown to lead to faster pro-
gression of liver fibrosis. Combination therapy for HCV
with pegylated interferon-alpha and ribavirin (pegIFN/
RBV) results in comparable sustained virological response
(SVR) rates for HIV/HCV co-infected patients vs. HCV
mono-infected patients. Monitoring early viral kinetics,
specifically baseline HCV viral load and week 4 HCV PCR
can allow tailoring of treatment duration for specific
patients and give prognostic information regarding pri-
mary treatment success.
Methods
98 HIV/HCV co-infected patients were commenced on
treatment with pegIFN/RBV between 2001 and 2008.
Early viral kinetic data was prospectively collected on 87/
98 patients and these were included in our analysis. Gen-
otype 2/3 infected patients were treated for 24 weeks.
Weight-based dosing of RBV was used. Baseline character-
istics and viral kinetics were analysed using Microsoft
EXCEL and Epi-Info.
Summary of results
68/87 (78%) were male. 41/87 (47%) of patients had
genotype 1/4 infection. On intention-to-treat analysis
(ITT), overall SVR rate was 54%. Baseline mean HCV viral
load was noted to be lower in those who achieved a SVR
(6 × 106 iu vs. 14 × 106 iu; p < 0.05). On ITT analysis 38/
87 (44%) achieved an undetectable HCV viral load at
week 4 of treatment (rapid virological response [RVR]).
Patients who achieved RVR were significantly more likely
to achieve SVR (90% vs. 26%; p < 0.05. On-treatment
analysis revealed that 100% of patients with RVR achieved
SVR. Predictors of RVR were mean HCV viral load <6 ×
106 at baseline (p < 0.05) and HCV genotype 2/3 (p <
0.05).
Conclusion
Monitoring of early viral kinetics can be used to accurately
predict those patients who will achieve SVR, especially
those for whom only 24 weeks of therapy is required.
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